<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03308669</url>
  </required_header>
  <id_info>
    <org_study_id>16925</org_study_id>
    <secondary_id>H8H-MC-LAHT</secondary_id>
    <nct_id>NCT03308669</nct_id>
  </id_info>
  <brief_title>A Study of Lasmiditan in Healthy Participants When Co-administered With Topiramate</brief_title>
  <official_title>Safety, Tolerability, and Pharmacokinetics of Lasmiditan When Co-administered With Topiramate in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety, tolerability and blood concentrations of lasmiditan and
      topiramate together compared to lasmiditan and topiramate separately. Information about any
      side effects that may occur will be collected.

      Participants will be admitted to the Clinical Research Unit (CRU) one day prior to the start
      of the study and will remain through Day 14.

      This study is expected to last approximately 25 days, not including screening. Screening is
      required within 28 days prior to the start of the study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 16, 2017</start_date>
  <completion_date type="Actual">December 2, 2017</completion_date>
  <primary_completion_date type="Actual">December 2, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline through Day 16</time_frame>
    <description>A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Lasmiditan, Topiramate, and Lasmiditan with Topiramate</measure>
    <time_frame>Predose up to 48 hours after administration of study drug on Days 1, 13 and 14</time_frame>
    <description>PK: Cmax of Lasmiditan, Topiramate, and Lasmiditan with Topiramate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration versus Time Curve (AUC) of Lasmiditan, Topiramate, and Lasmiditan with Topiramate</measure>
    <time_frame>Predose up to 48 hours after administration of study drug on Days 1, 13 and 14</time_frame>
    <description>PK: AUC of Lasmiditan, Topiramate, and Lasmiditan with Topiramate</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Lasmiditan Alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lasmiditan administered orally, alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Alone</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered orally, alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topiramate + Lasmiditan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topiramate administered orally, alone, and co-administered with oral lasmiditan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topiramate + Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topiramate administered orally, alone, and co-administered with oral placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lasmiditan</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Lasmiditan Alone</arm_group_label>
    <arm_group_label>Topiramate + Lasmiditan</arm_group_label>
    <other_name>LY573144</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Placebo Alone</arm_group_label>
    <arm_group_label>Topiramate + Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topiramate</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Topiramate + Lasmiditan</arm_group_label>
    <arm_group_label>Topiramate + Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are healthy males or females (of non-child bearing potential), as determined by
             medical history and physical examination

          -  Have a body mass index of 19.0 to 35.0 kilograms per meter squared (kg/m²) inclusive

        Exclusion Criteria:

          -  Have known allergies to lasmiditan, topiramate, related compounds or any components of
             the formulation of lasmiditan or topiramate

          -  Have an abnormal supine blood pressure, defined as systolic blood pressure less than
             (&lt;) 90 or great (&gt;) 140 millimeters of mercury (mmHg) or diastolic blood pressure &lt;60
             or &gt;90 mmHg at screening

          -  Have known or ongoing psychiatric disorders considered clinically significant by the
             investigator or demonstrate suicidal ideation on the Columbia Suicide Severity Rating
             Scale (C-SSRS)

          -  Have a clinically significant abnormality in the neurological examination

          -  Have current or a history of orthostatic hypotension (&gt;20-mmHg drop in systolic blood
             pressure, or &gt;10-mmHg drop in diastolic blood pressure) with or without dizziness
             and/or syncope at screening or admission to the Clinical Research Unit (CRU) upon
             repeat testing

          -  Have an estimated glomerular filtration rate using Modification of Diet in Renal
             Disease &lt;60 milliliter per minute (mL/min) per 1.73 meter squared (m²)

          -  Have a history of glaucoma

          -  Have a history of galactose intolerance, Lapp lactase deficiency, or glucose-galactose
             malabsorption
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Madison CRU</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2017</study_first_submitted>
  <study_first_submitted_qc>October 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2017</study_first_posted>
  <last_update_submitted>January 26, 2018</last_update_submitted>
  <last_update_submitted_qc>January 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topiramate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

